Beta Bionics (BBNX) Q4 2024 earnings summary

Executive summary

• iLet Bionic Pancreas launched in May 2023, rapidly expanding its installed base and market share in the underpenetrated U.S. insulin pump market, with over 15,000 users by year-end 2024.

• Net sales reached $65.1 million in 2024, up 443% year-over-year, driven by rapid iLet adoption and expanded pharmacy channel access.

• Completed IPO and private placement, raising $206 million in net proceeds to support innovation and growth.

• iLet’s adaptive closed-loop algorithm delivers all insulin doses with minimal user input, differentiating it from competitors.

• Company is focused on simplifying diabetes management and expanding access through innovative technology and business models.

Financial highlights

• Q4 2024 net sales were $20.4 million, up 145% year-over-year; full year net sales reached $65.1 million, up 443%.

• Gross margin for 2024 was 55.1%, with Q4 gross margin at 57.2%.

• Q4 2024 net loss was $18.1 million; adjusted EBITDA for Q4 was ($11.3 million).

• Operating expenses in Q4 were $24.7 million, including a $3 million milestone payment.

• Ended 2024 with $103.6 million in cash and equivalents.

Outlook and guidance

• 2025 revenue guidance is $80–$85 million, with gross margin expected to be at least 50%.

• Over 20% of new patient starts anticipated through the pharmacy channel in 2025, up from a high single-digit/low-teens percentage in 2024.

• Revenue and new patient starts expected to be weighted toward the back half of 2025 due to seasonality and pharmacy channel growth.

• Expansion to 63 sales territories and deeper pharmacy coverage expected to drive growth.